文献速递骨质疏松与代谢性骨病

韩国骨质疏松女性中每月一次口服伊班膦酸与利塞膦酸疗效比较:一项全国性人群研究

Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
PubMed 文献 · Osteoporos Int · 2018-12-08

该回顾性队列研究利用韩国国民健康保险服务老年人队列数据库,纳入2006至2015年60岁及以上韩国女性,比较每月一次口服伊班膦酸150 mg与利塞膦酸150 mg的抗骨折疗效。经倾向性评分匹配后每组各3454例,随访4年,伊班膦酸组总体骨折和非椎体骨折发生率均显著低于利塞膦酸组。

要点

  • 伊班膦酸组总体骨折发生率显著低于利塞膦酸组(IRR 0.822,95% CI 0.698-0.968)。
  • 伊班膦酸组非椎体骨折发生率显著低于利塞膦酸组(IRR 0.798,95% CI 0.647-0.985,P=0.036)。
  • 作者结论认为每月一次伊班膦酸150 mg抗骨折疗效优于利塞膦酸150 mg,但需进一步大规模研究确认。

核心结论

  • 每月一次伊班膦酸150 mg的抗骨折疗效优于每月一次利塞膦酸150 mg。
  • 作者指出需进一步大规模研究以确认上述发现并明确部位特异性差异,尤其是椎体和髋部区域。

研究设计与样本

  • 回顾性队列研究,使用韩国国民健康保险服务老年人队列全国性数据库。
  • 纳入2006至2015年年龄≥60岁的韩国女性,为新处方每月一次口服双膦酸盐者。
  • 主要结局为首次处方双膦酸盐后发生骨质疏松相关骨折。
  • 采用Cox比例风险模型估计总体骨折及部位特异性骨折的发生率比(IRR)及95%置信区间(CI),并校正可能的混杂因素。
  • 经倾向性评分匹配后,从36701例新使用每月一次伊班膦酸或利塞膦酸者中组建伊班膦酸组和利塞膦酸组,每组各3454例。

主要发现

  • 随访4年后,伊班膦酸组总体骨折发生率显著低于利塞膦酸组(IRR 0.822,95% CI 0.698-0.968,P=0.919)。
  • 随访4年后,伊班膦酸组非椎体骨折发生率显著低于利塞膦酸组(IRR 0.798,95% CI 0.647-0.985,P=0.036)。

局限性

  • 作者指出需进一步大规模研究以确认上述发现并明确部位特异性差异,尤其是椎体和髋部区域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Using a nationwide database from the Korean National Health Insurance Service, this study showed that once-monthly oral ibandronate (150 mg) had better anti-fracture efficacy than once-monthly oral risedronate (150 mg), as seen on assessing overall and non-vertebral fractures among Korean elderly women with osteoporosis. INTRODUCTION: Once-monthly oral bisphosphonates have been used widely without appropriate comparison. Therefore, we aimed to compare the anti-fracture efficacy of once-monthly ibandronate (150 mg) and once-monthly risedronate (150 mg). METHODS: We conducted a retrospective cohort study among Korean women aged ≥ 60 years from 2006 to 2015 using a nationwide database from the National Health Insurance Service Senior Cohort. The primary outcome was the first occurrence of fracture related to osteoporosis after the initial prescription of bisphosphonates. A Cox proportional model was used to estimate the incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for overall and site-specific fractures between the two treatments, after adjusting for possible confounding factors. RESULTS: After propensity score matching, the ibandronate and risedronate groups, with 3454 patients each, were assembled from 36,701 new once-monthly ibandronate or risedronate users. After 4 years of follow-up, the ibandronate group had significantly lower incidence rates of overall and non-vertebral fractures than the risedronate group (IRR 0.822, 95% CI 0.698-0.968, P = 0.919 and IRR 0.798, 95% CI 0.647-0.985, P = 0.036, respectively). CONCLUSIONS: Once-monthly ibandronate (150 mg) shows better anti-fracture efficacy than once-monthly risedronate (150 mg). However, further large-scale studies are required to confirm our findings and to determine site-specific differences, especially regarding the vertebral and hip areas.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Lee DR, Lee J. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study. Osteoporos Int. 2018. PMID: 30535785. doi:10.1007/s00198-018-4778-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。